Go Pro

BTIG Research's Rating of Serina Therapeutics on 7/1/2026

On July 1, 2026, BTIG Research updated its outlook on Serina Therapeutics (NYSEAMERICAN:SER) with the action "Initiated Coverage", setting a "Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from BTIG Research

DateCompanyAction
7/7/2026
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
Reiterated Rating
7/7/2026
Compass Pathways PLC Sponsored ADR stock logo
CMPS
Compass Pathways
Boost Price Target
7/7/2026
Invivyd, Inc. stock logo
IVVD
Invivyd
Reiterated Rating
7/7/2026
Upstart Holdings, Inc. stock logo
UPST
Upstart
Reiterated Rating
7/6/2026
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
Reiterated Rating
7/1/2026
Serina Therapeutics, Inc. stock logo
SER
Serina Therapeutics
Initiated Coverage
More Ratings From BTIG Research